Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs bariatric surgery for diabetes remission in obese type 2 diabetes
ChiCTR2100052902Phase 4Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Diabetes remission (HbA1c ≤ 6.5% with or without diabetes medications for ≥3 months). Started Jan 2022; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2100052902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052902.